FIGURE

Fig. 6

ID

ZDB-FIG-220725-12

Publication

Nunes et al., 2022 - RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition

Other Figures

All Figure Page

Back to All Figure Page

Fig. 6

Fig. 6. Phenotypic effects of combined RRM2-ATR pharmacological inhibition are opposed through the activation of a DNA-PK salvage pathway.

(A) IncuCyte live cell imaging indicates a drug synergism between RRM2 and the ATR inhibitor BAY1895543 that could not be shown in normal fibroblast cells (NIH3T3). (B) Combined RRM2-ATR inhibition leads to a significant induction of apoptosis compared to control or single compound–treated neuroblastoma cells while leaving NIH3T3 cells unaffected. (C) RT-qPCR analysis for CDKN1A, RRM2B, NOXA, PUMA, and BAX in IMR-32 and CLB-GA neuroblastoma cells following control (DMSO), single (3AP or BAY1895543), or combined (3AP and BAY1895543) drug treatment. (D) Immunoblotting for various DNA damage markers in IMR-32 and CLB-GA cells upon treatment with DMSO, 3AP, or BAY1895344 as a single agent or combined treatment of 3AP with BAY1895344.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Sci Adv